ROSWELL PARK CANCER INSTITUTE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Effects of Tobacco Flavoring and Liquid Composition on Vaping Topography

Not Applicable

Recruiting

Conditions: Tobacco-Related Carcinoma

Interventions: Other: Vaping
Procedure: Biospecimen Collection
Other: Questionnaire Administration

First Posted Date: 2023-05-25

Last Posted Date: 2024-05-14

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 72

Registration Number: NCT05876091

Locations: 🇺🇸
Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States

Evaluating the Episodic Future Thinking Intervention for Reducing Cigarette Consumption in Cigarette Smokers

Not Applicable

Recruiting

Conditions: Cigarette Smoking-Related Carcinoma

Interventions: Behavioral: Smoking Cessation Intervention (control)
Behavioral: Smoking Cessation Intervention
Other: Medical Device Usage and Evaluation

First Posted Date: 2023-04-24

Last Posted Date: 2024-10-16

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 96

Registration Number: NCT05825001

Locations: 🇺🇸
Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States

Home-based Respiratory Muscle Training for Minimizing Side Effects in Patients Undergoing Treatment for Breast Cancer

Not Applicable

Recruiting

Conditions: Breast Carcinoma

Interventions: Other: Best Practice
Other: Medical Device Usage and Evaluation
Procedure: Respiratory Muscle Training
Other: Survey Administration

First Posted Date: 2023-03-28

Last Posted Date: 2024-03-07

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 130

Registration Number: NCT05787834

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Weight Loss Interventions to Reduce Cancer Progression in Prostate Cancer Patients Under Active Surveillance

Not Applicable

Recruiting

Conditions: Prostate Carcinoma

Interventions: Procedure: Biospecimen Collection
Other: Dietary Intervention
Behavioral: Fasting

First Posted Date: 2023-03-10

Last Posted Date: 2024-06-03

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 20

Registration Number: NCT05764330

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer

Phase 1

Recruiting

Conditions: Anatomic Stage IV Breast Cancer AJCC v8
Unresectable Triple-Negative Breast Carcinoma
Metastatic Triple-Negative Breast Carcinoma

Interventions: Procedure: Biospecimen Collection
Procedure: Biopsy
Drug: Celecoxib
Procedure: Computed Tomography
Biological: Interferon Alpha-2
Procedure: Magnetic Resonance Imaging
Biological: Pembrolizumab
Drug: Rintatolimod

First Posted Date: 2023-03-06

Last Posted Date: 2024-05-30

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 12

Registration Number: NCT05756166

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Propranolol and Pembrolizumab for Tumor Re-sensitization and Treatment of Patients With Checkpoint Inhibitor Refractory Metastatic or Unresectable Triple Negative Breast Cancer

Phase 2

Recruiting

Conditions: Anatomic Stage IV Breast Cancer AJCC v8
Anatomic Stage III Breast Cancer AJCC v8
Metastatic Triple-Negative Breast Carcinoma
Refractory Triple-Negative Breast Carcinoma
Unresectable Triple-Negative Breast Carcinoma

Interventions: Procedure: Biopsy
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Biological: Pembrolizumab
Drug: Propranolol
Other: Questionnaire Administration

First Posted Date: 2023-02-23

Last Posted Date: 2024-11-18

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 25

Registration Number: NCT05741164

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Propranolol in Combination With Pembrolizumab and Standard Chemotherapy for the Treatment of Unresectable Locally Advanced or Metastatic Esophageal or Gastroesophageal Junction Adenocarcinoma

Phase 2

Recruiting

Conditions: Locally Advanced Gastroesophageal Junction Adenocarcinoma
Clinical Stage II Esophageal Adenocarcinoma AJCC v8
Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8
Clinical Stage III Esophageal Adenocarcinoma AJCC v8
Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8
Locally Advanced Esophageal Adenocarcinoma
Metastatic Gastroesophageal Junction Adenocarcinoma
Unresectable Esophageal Adenocarcinoma
Unresectable Gastroesophageal Junction Adenocarcinoma
Clinical Stage IV Esophageal Adenocarcinoma AJCC v8

Interventions: Procedure: Biopsy
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Drug: Fluorouracil
Drug: Leucovorin
Drug: Oxaliplatin
Biological: Pembrolizumab
Drug: Propranolol Hydrochloride
Other: Questionnaire Administration

First Posted Date: 2022-12-15

Last Posted Date: 2024-06-14

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 40

Registration Number: NCT05651594

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

A Cytomegalovirus-Directed Vaccine (CMV-alphaDC1) for Preventing Cytomegalovirus Infection or Reactivation in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Phase 1

Withdrawn

Conditions: Cytomegaloviral Infection
Hematopoietic and Lymphoid System Neoplasm

Interventions: Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
Procedure: Biospecimen Collection
Biological: CMV pp65 Peptide-loaded Alpha-type-1 Polarized Dendritic Cell Vaccine

First Posted Date: 2022-10-21

Last Posted Date: 2023-04-27

Lead Sponsor: Roswell Park Cancer Institute

Registration Number: NCT05589844

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Behavioral Parenting Skills As A Novel Target for Improving Pediatric Medication Adherence

Active, not recruiting

Conditions: Acute Lymphoblastic Leukemia

Interventions: Other: Survey Administration

First Posted Date: 2022-10-20

Last Posted Date: 2024-11-12

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 51

Registration Number: NCT05587582

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Dendritic Cell-Based Treatment Plus Immunotherapy for the Treatment of Metastatic or Unresectable Triple Negative Breast Cancer

Phase 2

Not yet recruiting

Conditions: Unresectable Triple-Negative Breast Carcinoma
Metastatic Triple-Negative Breast Carcinoma
Anatomic Stage III Breast Cancer AJCC v8
Anatomic Stage IV Breast Cancer AJCC v8

Interventions: Biological: Alpha-type-1 Polarized Dendritic Cells
Procedure: Biopsy
Procedure: Computed Tomography
Procedure: Leukapheresis
Biological: Pembrolizumab
Other: Quality-of-Life Assessment

First Posted Date: 2022-09-14

Last Posted Date: 2024-12-13

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 19

Registration Number: NCT05539365

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy